The past several years have witnessed a resurgence of interest in classic psychedelics (e.g., psilocybin, LSD, DMT) and empathogens/entactogens (e.g., MDMA) for their potential therapeutic applications in a range of psychiatric conditions, including major depressive disorder, treatment-resistant depression, PTSD, and substance use disorders. Although psilocybin and MDMA are now in late-stage FDA regulatory clinical trials, there is still a paucity of adequately powered, randomized, controlled data on the efficacy, tolerability and safety of these approaches. Major unresolved issues include the role of “set and setting” and non-drug factors in the potential benefit of these approaches, and the optimal delivery of psychedelic-assisted psychotherapy for patients.

This webinar brought together several leading experts to provide their clinical and research perspectives on the psychedelic medicine field as it pertains to depression, anxiety, and PTSD.

A leading academic psychiatry expert (Dr. Carhart-Harris) was the keynote speaker and discussed the state of the science for psilocybin in depression, including a discussion of its history, neuropsychopharmacology, clinical effects, and safety.

This keynote lecture was followed by a panel discussion including leading clinical and research faculty experts in classic psychedelics and MDMA (Drs. Carhart-Harris, Fonzo, Yehuda, and Ross) who discuss emerging scientific, clinical, and regulatory challenges for the field.

Keynote Presentation | Psychedelics: Brain Mechanisms Featuring Robin Carhart-Harris, PhD

Panel Discussion | Psychedelic Therapy: Problems and Promises Featuring Robin Carhart-Harris, PhD, Greg Fonzo, PhD, Stephen Ross, MD, and Rachel Yehuda, PhD